NCT07138274View on ClinicalTrials.gov

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

June 30, 2031

Study Completion Date

December 31, 2031

Conditions
Mild Autonomous Cortisol Secretion (MACS)Autonomous Cortisol Secretion (ACS)
Interventions
DRUG

Metyrapone 250 mg Oral Tablets

Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg

DRUG

Placebo

Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER